Aggressive dose de-escalation of radiotherapy provides similar efficacy and superior safety profile in patients with human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), according to a recent study presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Hypofractionated radiotherapy (HFRT) is equally effective and safe compared with conventional fractionated RT (CFRT) in Chinese breast cancer patients who have undergone mastectomy, according to a phase III study presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Meeting. [ASTRO 2017, abstract 5]
Use of consolidative stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy improves progression-free survival (PFS) by more than 6 months in patients with non-small-cell lung cancer (NSCLC) who have limited metastases, a recent phase II study has shown. [ASTRO 2017, abstract LBA3; JAMA Oncol 2017, doi: 10.1001/jamaoncol.2017.3501]
Combination therapy with the CTLA-4 blocker, ipilimumab, and stereotactic ablative radiation therapy (SABR) is effective in cancers with metastatic lung and liver lesions, according to results presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).